Morgan Stanley raised the price target for the Bausch + Lomb Corp (NYSE:BLCO) stock from “an Equal-weight” to “an Overweight”. The rating was released on May 06, 2024, according to finviz. We ...

In today's trading, Bausch Lomb Corporation shares opened at $20.83 and closed at $19.92. prices ranged from a low of $19.92 to a high of $20.83. Shares dipped -4.05% from the previous day's close of ...

Detailed price information for Bausch Lomb Corporation (BLCO-T) from The Globe and Mail including charting and trades.

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea ...

LAVAL, QC / ACCESSWIRE / May 15, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) today announced the results of its 2024 annual meeting of shareholders.

We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling ...

The judgment in the case of Bausch and Lomb India Private Limited vs. Assessment Unit, National Faceless Assessment Centre serves as a reminder of the significance of procedural fairness and due ...

Bausch + Lomb Corporation (NYSE:BLCO) Q1 2024 Earnings Call Transcript May 1, 2024 Bausch + Lomb Corporation misses on earnings expectations. Reported EPS is $0.07 EPS, expectations were $0.09.

LAVAL, QC / ACCESSWIRE / May 15, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the results of its 2024 annual meeting of shareholders.Annual Meeting ResultsThe 10 directors n ...

LAVAL, QC / ACCESSWIRE / May 14, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business Salix Pharmaceuticals, today announced certain updates related to its litigat ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Oncolytics Biotech (ONCY – Research Report), Aveanna ...